MAP2K7 and cardiofaciocutaneous syndrome: MEK inhibitors are being investigated, and in some cases prescribed as first-line therapy, in NF1 and other RASopathy syndromes, including Noonan syndrome, hypertrophic cardiomyopathy, multifocal atrial tachycardia (MAT), lymphatic anomalies, capillary–arteriovenous malformations, Kaposiform lymphangiomatosis, and cardiofaciocutaneous syndrome, among others.